Chondroitin Polymerizing Factor (CHPF) promotes cell proliferation and tumor growth in human osteosarcoma by inhibiting SKP2's ubiquitination while activating the AKT pathway

Yi Shen; Jun Li; Dan Peng; Lele Liao; Xia Chen; Weiye Zhong; Zicheng Liu; Chao Yu; Yuanliang Sun

doi:10.1016/j.gendis.2022.06.010

您当前的位置：

首页 >

文章列表页 >

Chondroitin Polymerizing Factor (CHPF) promotes cell proliferation and tumor growth in human osteosarcoma by inhibiting SKP2's ubiquitination while activating the AKT pathway

Full-length article | 更新时间：2023-08-29

- Chondroitin Polymerizing Factor (CHPF) promotes cell proliferation and tumor growth in human osteosarcoma by inhibiting SKP2's ubiquitination while activating the AKT pathway
- Genes & Diseases Vol. 10, Issue 5, (2023)
- 作者机构：
  
  1. Department of Orthopaedics, The Second Xiangya Hospital of Central South University,Hunan,Changsha,China,410000
  2. Department of Spine Surgery, Affiliated Hospital of Qingdao University,Shandong,Qingdao,China,266000
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2022.06.010
  CLC：
- Published：2023，
  
  Published Online：1 September 2023，
扫描看全文
Yi Shen, Jun Li, Dan Peng, et al. Chondroitin Polymerizing Factor (CHPF) promotes cell proliferation and tumor growth in human osteosarcoma by inhibiting SKP2's ubiquitination while activating the AKT pathway. [J]. Genes & Diseases 10(5).(2023)
DOI：

Yi Shen, Jun Li, Dan Peng, et al. Chondroitin Polymerizing Factor (CHPF) promotes cell proliferation and tumor growth in human osteosarcoma by inhibiting SKP2's ubiquitination while activating the AKT pathway. [J]. Genes & Diseases 10(5).(2023) DOI： 10.1016/j.gendis.2022.06.010.

摘要

Abstract

Osteosarcoma is a common malignant tumor occurring in children and young adults. Chondroitin sulfate (CS) participates in cell adhesion

cell division

and the formation of neural networks in the body

the biosynthesis of which requires the participation of glycosyltransferases. CHPF

a glycosyltransferase

plays a role in the extension of CS. Recently

CHPF's biological roles and functional importance in human diseases including malignant tumors have been widely discussed. However

whether CHPF is involved in osteosarcoma development and growth has not been revealed. The present work aimed to investigate the expression levels

functional significance and molecular mechanism of CHPF in osteosarcoma progression. Our results revealed that CHPF is strongly expressed in osteosarcoma tissues and cells. Furthermore

CHPF serves as a tumor promoter in the development and progression of osteosarcoma through enhancing cell proliferation and migration while suppressing apoptosis. Exploration of the mechanism by which CHPF promotes osteosarcoma indicated that CHPF promotes osteosarcoma through counteracting SKP2's ubiquitination and activating the Akt signaling pathway. For the first time

we clarified the roles of CHPF in osteosarcoma

and our results suggested that CHPF might be a novel therapeutic target in the treatment strategies for osteosarcoma.

关键词

Keywords

Akt signaling pathwayCHPFOsteosarcomaSKP2Ubiquitination

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

The generation and use of animal models of osteosarcoma in cancer research

Integrative transcriptome analysis identifies MYBL2 as a poor prognosis marker for osteosarcoma and a pan-cancer marker of immune infiltration

Aberrant LETM1 elevation dysregulates mitochondrial functions and energy metabolism and promotes lung metastasis in osteosarcoma

Cellular senescence-driven transcriptional reprogramming of the MAFB/NOTCH3 axis activates the PI3K/AKT pathway and promotes osteosarcoma progression

Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy

Related Author

Feifei Pu

Haoyu Guo

Deyao Shi

Fengxia Chen

Yizhong Peng

Xin Huang

Jianxiang Liu

Zhicai Zhang

Related Institution

Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Department of Radiation and Medical Oncology, Zhongnan Hospital, Wuhan University

Department of Orthopedics, Wuhan Hospital of Traditional Chinese and Western Medicine (Wuhan No.1 Hospital), Tongji Medical College, Huazhong University of Science and Technology

Hubei Cancer Clinical Study Center, Zhongnan Hospital, Wuhan University

National Clinical Research Center for Geriatric Disorders, Xiangya Hospital

⁰